Cohen Veterans Network Unveils New Awareness Campaign, 'PTSD: What Therapists Want You to Know'
STAMFORD, Conn., June 11, 2025 /PRNewswire/ -- This June, coinciding with PTSD Awareness Month, Cohen Veterans Network (CVN), a national not-for-profit network of mental health clinics for post-9/11 veterans, service members, and their families, is launching a new public awareness campaign, "PTSD: What Therapists Want You to Know." The initiative features a video series with key insights from mental health experts who specialize in treating trauma and PTSD. The campaign aims to challenge misconceptions about the disorder and underscore that effective treatments are available.
Posttraumatic Stress Disorder (PTSD) is a mental health disorder that some people develop after experiencing or witnessing a life-threatening event, like combat, a natural disaster, a car accident, or sexual assault. The U.S. Department of Veterans Affairs reports that at some point in their life, seven out of every 100 veterans (7%) will have PTSD. This rate is similar to that of the U.S. population in which six of every 100 adults (6%) will have PTSD in their lifetime. Currently, there are about 12 million people in the U.S. with PTSD.
"PTSD is often misunderstood, leading to stigma and misinformation that can prevent people from seeking help," said Dr. Anthony Hassan, president and CEO of Cohen Veterans Network. "By increasing awareness and understanding about the disorder, we hope to empower more individuals to take that first step toward care. PTSD is treatable, recovery is possible, and support is available."
The campaign features a series of short, informative videos with information and advice from therapists who work with PTSD every day. The videos address common questions and misconceptions, exploring topics such as why two people can respond differently to the same trauma, what causes PTSD, how to make the most out of trauma treatment, and the importance of using the term "PTSD" accurately. The campaign additionally features an article on Explaining PTSD to Kids: Four Steps for Parents, which provides strategies to help caregivers talk with children about PTSD in the home.
Since 2016, CVN has cared for over 85,000 clients and provided more than 770,000 clinical sessions. Approximately 21% of the network's veteran and active duty clients have received treatment for PTSD. The network additionally treats a wide variety of mental health concerns including depression, anxiety, military transition challenges, adjustment issues, anger, grief and loss, family issues, relationship challenges, and children's behavioral problems. Care is available through the network's 22 Cohen Clinics serving 20 states
in-person and via CVN Telehealth, face-to-face video therapy.
For more information on "PTSD What Therapists Want You to Know" or to access the campaign video series and resources, visit cohenveteransnetwork.org/ptsd.
Cohen Clinic b-roll is available here.
ABOUT COHEN VETERANS NETWORK
Cohen Veterans Network (CVN) is a 501(c)(3) national not-for-profit philanthropic organization for post- 9/11 veterans, active duty service members and their families. CVN focuses on improving mental health outcomes, operating a network of outpatient mental health clinics in high-need communities, in which trained clinicians deliver holistic evidence-based care to treat mental health conditions. It was established in 2016 by philanthropist Steven A. Cohen with a commitment of $275 million to build the network. Learn more about CVN at cohenveteransnetwork.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cohen-veterans-network-unveils-new-awareness-campaign-ptsd-what-therapists-want-you-to-know-302478999.html
SOURCE Cohen Veterans Network
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Evernow Partners with ŌURA to Combine Symptom Tracking with Personalized Menopause Care
SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Evernow, the leading telehealth platform for menopause care, is proud to announce a partnership with ŌURA, maker of the world's leading smart ring. As part of the launch of Oura's first-ever menopause feature, Perimenopause Check-In, Evernow will serve as a care partner to transform insight into action. Perimenopause is one of the most underrecognized phases in women's health, often lasting years and affecting everything from mood to sleep to cognitive clarity. Despite its widespread impact, many women struggle to get meaningful answers or support. By integrating real-time biometric data with access to expert care, this collaboration offers a new, proactive model for managing early hormonal changes. Oura members who complete the Perimenopause Check-In can now seamlessly access Evernow's clinician-led care, with the option to upload personalized Oura reports (including Sleep, Cycle, and Perimenopause data) directly before their visit. Evernow clinicians will use this data to inform and personalize treatment plans, connecting symptom awareness to timely, evidence-based care. "Millions of women are experiencing symptoms related to perimenopause, but haven't had the language or tools to act," said Alicia Jackson, CEO of Evernow. "This partnership helps them do both: understand what's happening in their bodies and connect with specially trained clinicians who can create tailored treatment plans, prescribe medication when appropriate, and offer guidance on managing symptoms day-to-day." Through the partnership with Evernow, Oura members can access: Video visits with menopause-trained clinicians in under 48 hours Insurance-covered menopause care across all 50 states Unlimited messaging with your provider Personalized treatment plans informed by Oura biometric reports Easy, convenient prescriptions with automated refills Learn more at Together, Evernow and Oura are making it easier for women to go from tracking symptoms to getting real care, bringing clarity, support, and faster access to treatment during one of the most overlooked stages of women's health. Contact:press@ View original content: SOURCE Evernow Sign in to access your portfolio
Yahoo
12 hours ago
- Yahoo
Enterprise Imaging IT Market worth US$4.12 Billion by 2030 with 12.2% CAGR
DELRAY BEACH, Fla., Aug. 14, 2025 /PRNewswire/ -- The global Enterprise Imaging IT Market, valued at US$2.08 billion in 2024, stood at US$2.31 billion in 2025 and is projected to advance at a resilient CAGR of 12.2% from 2025 to 2030, culminating in a forecasted valuation of US$4.12 billion by the end of the period. Growth is fueled by the increasing demand for cross-specialty image access in oncology and cardiology, along with the integration of advanced visualization tools like 3D and cinematic rendering into enterprise viewers. The rising adoption of mobile diagnostic imaging and point-of-care ultrasound is also pushing the need for centralized imaging data management. Moreover, the deployment of vendor-neutral archives (VNA) for longitudinal imaging records across networks is driving platform consolidation. However, limited standardization in imaging protocols across departments and high transition costs from legacy systems remain key restraints for market expansion. Download PDF Brochure: Browse in-depth TOC on "Enterprise Imaging IT Market" 434 - Tables 54 - Figures 411 - Pages By function, the market is divided into vendor-neutral archives (VNA), picture archiving and communication systems (PACS), image exchange, universal viewer, workflow orchestration, analytics, and other functions. The VNA segment is anticipated to expand at a considerable CAGR throughout the forecast period. The VNA market is propelled by the surge in non-DICOM data such as digital pathology slides, endoscopy videos, and point-of-care ultrasound clips, requiring a truly modality-agnostic repository. New regulations mandating extended retention of imaging for AI training purposes and medico-legal audits are also driving hospitals to replace siloed archives with VNAs that offer scalable, tamper-proof storage. Additionally, the push to integrate imaging into enterprise data lakes for advanced, cross discipline analytics is encouraging providers to invest in VNAs with native API frameworks and cloud bursting capabilities. By offering, the enterprise imaging IT market is segmented into software and services. In 2024, the software segment held the largest market share of the enterprise imaging IT market globally. The significant market share of this segment can be attributed to the rapid shift toward subscription-based licensing models that lower upfront costs and align software spend with actual imaging volumes. Health systems are also demanding API first, microservices-based architectures that enable plug-and-play integration of imaging modules with EHRs, digital pathology, and genomics platforms. Moreover, vendors embedding real-time BI engines and customizable reporting dashboards directly into their core software are meeting the need for deep, modality-specific performance analytics. By geography, in 2024, North America held the largest market share for enterprise imaging IT. The large share of this region can be attributed to several factors, including the rapid shift toward image-enabled EHR systems that support real-time clinical decision-making across multi-specialty teams. The growing emphasis on imaging data monetization through research collaborations, AI training datasets, and secondary use licensing is also encouraging investments in robust enterprise imaging infrastructure. Furthermore, the widespread deployment of remote peer review and tumor board solutions across academic medical centers is driving demand for interoperable, enterprise-scale imaging platforms. Request Sample Pages : The prominent players in the enterprise imaging IT market include Agfa-Gevaert Group (Belgium), FUJIFILM Corporation (Japan), Merative (US), Pro Medicus, Ltd. (Australia), Optum, Inc. (US), GE HealthCare (US), Intelerad (Canada), Sectra AB (Sweden), CANON MEDICAL SYSTEMS CORPORATION (Japan), Hyland Software, Inc. (US), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers AG (Germany), INFINITT Healthcare Co., Ltd. (South Korea), Novarad (US), Mach7 Technologies (US), Hermes Medical Solutions (Sweden), Konica Minolta, Inc. (Japan), BridgeHead Software Ltd. (England), Sclmage, Inc. (US), VISUS Health IT GmbH (Germany), Dicom Systems, Inc. (US), PostDICOM (Netherlands), Qaelum (Belgium), AdvaHealth Solutions (Singapore), PaxeraHealth (US), and Rad AI (US). Agfa-Gevaert Group (Belgium) Agfa-Gevaert Group develops, produces, and distributes an extensive range of analog and digital imaging solutions, mainly for the healthcare sector and printing industry. The company operates through three business segments: Digital Print & Chemicals, HealthCare IT, and Radiology Solutions. Through its HealthCare IT division, the company delivers advanced imaging informatics solutions that support hospitals and healthcare networks in their digital transformation. Its enterprise imaging platform integrates radiology, cardiology, and other departmental imaging workflows into a unified system, enabling seamless image access, sharing, and collaboration across care teams. Agfa-Gevaert's offerings cater to a wide range of end users, including large hospital networks, academic medical centers, diagnostic imaging centers, and specialty clinics. Agfa HealthCare operates through a strong international network, with wholly owned sales organizations in over 40 countries and additional representation via agents and distributors across nearly 100 others. Its main enterprise imaging hubs and R&D/manufacturing sites are in Belgium, the US, Canada, Germany, China, Brazil, and other strategic regions, complemented by regional offices in key markets such as the Middle East and South Africa. GE HealthCare (US) GE HealthCare develops, manufactures, and markets a broad portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. The company has a large, global installed base of medical imaging, ultrasound, and patient monitoring systems. GE HealthCare operates mainly through four divisions: Imaging, Advanced Visualizing Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. On March 31, 2020, the company completed the sale of its Biopharma business segment to Danaher Corporation for USD 20,718 million. The company provides IT solutions, including enterprise and departmental information technology products, picture archiving systems (PACS), radiology information systems (RIS), cardiovascular information systems (CVIS), and practice applications. The main end users of the company's solutions include hospitals, pharmaceutical firms, biotechnology companies, medical facilities, and life science research bodies. GE HealthCare serves customers in over 160 countries, conducts R&D in 18 countries, and manufactures its products in 20 countries worldwide. The company has a geographical presence in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. For more information, Inquire Now! Related Reports: Diagnostic Imaging Market MRI Systems Market Healthcare IT Market Remote Patient Monitoring (RPM) Market IoT Medical Devices Market Get access to the latest updates on Enterprise Imaging Companies and Enterprise Imaging Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441 Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
12 hours ago
- Yahoo
Lateral Flow Assays Market worth $12.52 billion by 2030 with 8.0% CAGR
DELRAY BEACH, Fla., Aug. 14, 2025 /PRNewswire/ -- The global Lateral Flow Assays Market, valued at US$7.93 billion in 2024, stood at US$8.51 billion in 2025 and is projected to advance at a resilient CAGR of 8.0% from 2025 to 2030, culminating in a forecasted valuation of US$12.52 billion by the end of the period. The persistent rise in infectious diseases worldwide demands fast, accessible diagnostics, boosting the adoption of LFAs in diverse environments from hospitals and clinics to homes and remote clinics. Moreover, an aging global demographic is increasing the need for routine monitoring of chronic and cardiac conditions, encouraging broader use of home-based and point-of-care LFA solutions. Innovations such as smartphone-compatible readers, AI-powered analysis, and multiplex-capable assays further support this shift, improving usability, connectivity, and diagnostic precision. At the same time, extensive deployment of home testing kits, including pregnancy, fertility, and infectious markers self-tests, has boosted consumer acceptance and comfort with LFA devices, while regulatory approvals for POC and home-based LFAs reinforce market expansion. Adoption is tempered by notable constraints. LFAs often exhibit lower sensitivity and specificity than molecular or lab-based tests, leading to false-positive or false-negative outcomes and hindering widespread clinical acceptance. Download PDF Brochure: Browse in-depth TOC on "Lateral Flow Assays Market" 603 - Tables 59 - Figures 439 - Pages By technique, the lateral flow assay kits and reagents market is segmented into competitive, sandwich, and multiplex detection assays. Sandwich assays dominated the market, with a share in 2024. The large share of this segment can be attributed to the better assay sensitivity and specificity associated with sandwich assays and their extensive application in the measurement of critical analytes (such as cardiac and hepatitis markers). By sample type, the lateral flow assays market is segmented into blood, urine, saliva, and other samples (nasal swabs, throat swabs, and vaginal fluid). Blood samples accounted for the largest market share in 2024. Technological advancements in testing methods have also improved accuracy and reduced turnaround times, making these tests more appealing for both healthcare providers and patients. The extensive use of blood samples in lateral flow tests and the easy detection of disease antibodies from blood samples are the key factors driving the growth of this market segment. By geography, the lateral flow assays market is segmented into six major segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. North America accounts for the largest market share in the lateral flow assays market in 2024. North America is the leading region in the lateral flow assays market due to its advanced healthcare infrastructure and significant investments in medical technology innovation. The presence of major medical device manufacturers and growing LFA evolution, leading in smartphone-enabled readers, AI-powered result interpretation, and multiplex testing formats. Request Sample Pages : Prominent players in the lateral flow assays market include Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Surmodics, Inc. (US), and OraSure Technologies Inc. (US). Abbott Laboratories (US): Abbott is the leading player in the global lateral flow assay market, accounting for the largest share of the global LFA market in 2024. Its dominance stems from a diverse LFA portfolio encompassing infectious disease, cardiac, and consumer-based diagnostics, backed by robust continuous innovation. Abbott's strategic investments in reader-enabled and multiplex LFA formats, along with a strong global manufacturing footprint and R&D pipeline, reinforce its leadership position. The company's focus on benchtop reader integration and pharma/biotech QC applications signals its intent to stay ahead in high-value LFA segments, ensuring sustained competitive advantage. F. Hoffman-La Roche Ltd. (Switzerland) Roche is a key leader in the lateral flow assay space, accounting for the second-largest share of the global market. Known for its high-sensitivity LFA products, Roche has made strides in digital-read capabilities and advanced sandwich assays targeting infectious diseases and oncology screening. Its regular product refreshes and R&D expansion, including enhanced multiplex LFA formats, reflect its ongoing commitment to innovation. Roche's established global footprint and investment in smart diagnostic technologies position it as a formidable force in premium LFA segments, strengthening its presence during market transitions. Danaher Corporation (US) Danaher commands a significant share of the LFA market. Beyond components, its Life Sciences portfolio, bolstered by acquisitions like Pall and Cytiva, equips Danaher to influence next-generation LFA platforms for process development and QC in biopharma. In 2023, Danaher further solidified its position by acquiring Abcam, enhancing capabilities in research-stage diagnostics. With a strong operational backbone, strategic M&A strategy, and growing role in supplying membranes, conjugates, and benchtop instruments, Danaher is a key enabler of LFA innovation, powering the ecosystem behind major LFA brands. For more information, Inquire Now! Related Reports: Veterinary Infectious Disease Diagnostics Market Veterinary Diagnostics Market Companion Animal Diagnostics Market Immunoassay Market Point of Care Diagnostics Market Get access to the latest updates on Lateral Flow Assays Companies and Lateral Flow Assays Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
